Mostrar el registro sencillo del ítem

dc.contributor.authorAlbanell, J.
dc.contributor.authorGonzález, A.
dc.contributor.authorRuiz-Borrego, M
dc.contributor.authorAlba-Conejo, Emilio 
dc.contributor.authorGarcía-Saenz, J.A.
dc.contributor.authorCorominas, J. M.
dc.contributor.authorBurgues, O.
dc.contributor.authorFurio, V.
dc.contributor.authorRojo, A.
dc.contributor.authorPalacios, J.
dc.contributor.authorBermejo, B.
dc.contributor.authorMartínez-García, M.
dc.contributor.authorLimón, L.M.
dc.contributor.authorSánchez-Muñoz, Alfonso 
dc.contributor.authorMartín, M.
dc.contributor.authorTusquets, I.
dc.contributor.authorRojo, R.
dc.contributor.authorColomer, R.
dc.contributor.authorFaull, F.
dc.contributor.authorLluch, A.
dc.date.accessioned2024-01-31T12:44:33Z
dc.date.available2024-01-31T12:44:33Z
dc.date.issued2012-03
dc.identifier.citationAlbanell J, González A, Ruiz-Borrego M, Alba E, García-Saenz JA, Corominas JM, Burgues O, Furio V, Rojo A, Palacios J, Bermejo B, Martínez-García M, Limon ML, Muñoz AS, Martín M, Tusquets I, Rojo F, Colomer R, Faull I, Lluch A. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Ann Oncol. 2012 Mar;23(3):625-631. doi: 10.1093/annonc/mdr278. Epub 2011 Jun 6. PMID: 21652577.es_ES
dc.identifier.urihttps://hdl.handle.net/10630/29523
dc.descriptionEste artículo ha sido publicado en Annals of Oncology. Esta versión tiene Licencia Creative Commons CC-BY.es_ES
dc.description.abstractThis study examined the impact of the Recurrence Score (RS) in Spanish breast cancer patients and explored the associations between clinicopathological markers and likelihood of change in treatment recommendations. Patients and methods: Enrollment was offered consecutively to eligible women with estrogen receptor-positive; human epidermal growth factor receptor 2-negative, node-negative breast cancer. Oncologists recorded treatment recommendation and confidence in it before and after knowing the patient’s RS. Results: Treatment recommendation changed in 32% of 107 patients enrolled: in 21% from chemohormonal (CHT) to hormonal therapy (HT) and in 11% from HT to CHT. RS was associated with the likelihood of change from HT to CHT (P < 0.001) and from CHT to HT (P < 0.001). Confidence of oncologists in treatment recommendations increased for 60% of cases. Higher tumor grade (P = 0.007) and a high proliferative index (Ki-67) (P = 0.023) were significantly associated with a greater chance of changing from HT to CHT, while positive progesterone receptor status (P = 0.002) with a greater probability of changing from CHT to HT. Conclusions: Results from the first prospective European study are consistent with published experience and use of the RS as proposed in European clinical practice guidelines and provide evidence on how Oncotype DX and clinicopathological factors are complementary and patient selection may be improved.es_ES
dc.description.sponsorshipThis work was supported in part by Plan Nacional de Investigacio´ n Cientı´fica, Desarrollo e Innovacio´ n Tecnolo´ gica (I + D + I), iniciativa Ingenio 2010, programa Consolider and Instituto de Salud Carlos III (ISCIII)/FEDER (RD06/0020/0109, RD06/0020/0080, RD06/002/002); PN de I + D + I 2008-20011, and ISCIII/FEDER—Subdireccio´n General de Evaluacio´n y Fomento de la Investigacio´n (PS09/01285, PS09/01700, PS09/ 01296 FIS PI04417, FIS PI082031, CIT-090000-2008-010,); DIUE Generalitat de Catalunya.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectMamas - Cánceres_ES
dc.subjectQuimioterapiaes_ES
dc.subject.otherBreast canceres_ES
dc.subject.otherChemotherapyes_ES
dc.subject.otherEstrogen receptor-positivees_ES
dc.subject.otherOncotype DXes_ES
dc.subject.otherRecurrences Scorees_ES
dc.subject.otherReceptor de estrógenos positivoes_ES
dc.subject.otherRiesgo de recurrenciaes_ES
dc.subject.otherRecidivaes_ES
dc.titleProspective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER1) node-negative breast canceres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.centroFacultad de Medicinaes_ES
dc.identifier.doi10.1093/annonc/mdr278
dc.rights.ccAtribución 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional